Talis Net Working Capital vs Total Liab Analysis

TLIS Stock

USD 9.20 0.10 1.10%

Talis Biomedical financial indicator trend analysis is much more than just breaking down Talis Biomedical Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Talis Biomedical Corp is a good investment. Please check the relationship between Talis Biomedical Net Working Capital and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talis Biomedical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

Net Working Capital vs Total Liab

Net Working Capital vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Talis Biomedical Corp Net Working Capital account and Total Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Talis Biomedical's Net Working Capital and Total Liab is 0.31. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Total Liab in the same time period over historical financial statements of Talis Biomedical Corp, assuming nothing else is changed. The correlation between historical values of Talis Biomedical's Net Working Capital and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Talis Biomedical Corp are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Working Capital i.e., Talis Biomedical's Net Working Capital and Total Liab go up and down completely randomly.

Correlation Coefficient

0.31

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Working Capital

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Talis Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Talis Biomedical Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talis Biomedical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

At this time, Talis Biomedical's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.75 in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2019	2020	2023	2024 (projected)
Interest Income	42K	54K	48.6K	50.4K
Net Interest Income	42K	54K	48.6K	50.4K

Interest Income Net Interest Income

Talis Biomedical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Property Plant Equipment
Total Assets		0.12	1.0	0.72	-0.81	0.7	0.83	-0.97	-0.73	0.86	0.99	0.85	0.94	0.66	0.99	-0.89	-0.71	0.18	0.94	0.61	0.26	0.72	0.78	1.0	1.0	0.7
Other Current Liab	0.12		0.09	0.43	-0.42	0.51	0.59	0.03	-0.67	-0.15	0.12	0.58	-0.18	-0.25	0.12	-0.44	0.11	-0.47	0.05	0.67	-0.45	0.43	0.7	0.05	0.05	0.68
Total Current Liabilities	1.0	0.09		0.68	-0.81	0.67	0.81	-0.97	-0.72	0.87	0.99	0.82	0.95	0.64	0.99	-0.89	-0.74	0.23	0.93	0.58	0.3	0.68	0.75	1.0	1.0	0.68
Total Stockholder Equity	0.72	0.43	0.68		-0.62	0.95	0.83	-0.72	-0.75	0.49	0.78	0.88	0.5	0.76	0.78	-0.7	-0.16	-0.53	0.6	0.89	-0.47	1.0	0.82	0.67	0.67	0.72
Other Liab	-0.81	-0.42	-0.81	-0.62		-0.69	-0.74	0.73	0.81	-0.55	-0.8	-0.76	-0.68	-0.33	-0.8	0.89	0.39	-0.06	-0.7	-0.65	-0.12	-0.62	-0.77	-0.8	-0.8	-0.78
Net Tangible Assets	0.7	0.51	0.67	0.95	-0.69		0.82	-0.65	-0.88	0.34	0.75	0.87	0.47	0.62	0.75	-0.8	-0.22	-0.54	0.5	0.97	-0.48	0.95	0.86	0.66	0.66	0.86
Property Plant And Equipment Net	0.83	0.59	0.81	0.83	-0.74	0.82		-0.75	-0.87	0.64	0.84	0.99	0.61	0.47	0.84	-0.86	-0.48	-0.17	0.78	0.83	-0.11	0.83	0.96	0.79	0.79	0.84
Net Debt	-0.97	0.03	-0.97	-0.72	0.73	-0.65	-0.75		0.6	-0.91	-0.98	-0.78	-0.95	-0.79	-0.98	0.79	0.65	-0.19	-0.95	-0.51	-0.27	-0.72	-0.68	-0.98	-0.98	-0.55
Retained Earnings	-0.73	-0.67	-0.72	-0.75	0.81	-0.88	-0.87	0.6		-0.34	-0.73	-0.89	-0.51	-0.29	-0.73	0.94	0.45	0.26	-0.53	-0.92	0.2	-0.75	-0.95	-0.69	-0.69	-1.0
Accounts Payable	0.86	-0.15	0.87	0.49	-0.55	0.34	0.64	-0.91	-0.34		0.85	0.63	0.9	0.66	0.85	-0.58	-0.66	0.44	0.98	0.21	0.5	0.49	0.5	0.88	0.88	0.28
Cash	0.99	0.12	0.99	0.78	-0.8	0.75	0.84	-0.98	-0.73	0.85		0.86	0.92	0.73	1.0	-0.88	-0.65	0.1	0.92	0.65	0.17	0.78	0.78	0.99	0.99	0.69
Non Current Assets Total	0.85	0.58	0.82	0.88	-0.76	0.87	0.99	-0.78	-0.89	0.63	0.86		0.63	0.53	0.86	-0.88	-0.47	-0.22	0.77	0.87	-0.15	0.88	0.97	0.8	0.8	0.87
Non Currrent Assets Other	0.94	-0.18	0.95	0.5	-0.68	0.47	0.61	-0.95	-0.51	0.9	0.92	0.63		0.65	0.92	-0.76	-0.8	0.44	0.91	0.33	0.51	0.5	0.55	0.96	0.96	0.47
Other Assets	0.66	-0.25	0.64	0.76	-0.33	0.62	0.47	-0.79	-0.29	0.66	0.73	0.53	0.65		0.73	-0.4	-0.23	-0.21	0.63	0.43	-0.15	0.76	0.38	0.67	0.67	0.24
Cash And Short Term Investments	0.99	0.12	0.99	0.78	-0.8	0.75	0.84	-0.98	-0.73	0.85	1.0	0.86	0.92	0.73		-0.88	-0.65	0.1	0.92	0.65	0.17	0.78	0.78	0.99	0.99	0.69
Net Receivables	-0.89	-0.44	-0.89	-0.7	0.89	-0.8	-0.86	0.79	0.94	-0.58	-0.88	-0.88	-0.76	-0.4	-0.88		0.65	-0.03	-0.73	-0.79	-0.09	-0.7	-0.9	-0.87	-0.87	-0.92
Common Stock Shares Outstanding	-0.71	0.11	-0.74	-0.16	0.39	-0.22	-0.48	0.65	0.45	-0.66	-0.65	-0.47	-0.8	-0.23	-0.65	0.65		-0.59	-0.67	-0.2	-0.63	-0.16	-0.45	-0.73	-0.73	-0.45
Non Current Liabilities Total	0.18	-0.47	0.23	-0.53	-0.06	-0.54	-0.17	-0.19	0.26	0.44	0.1	-0.22	0.44	-0.21	0.1	-0.03	-0.59		0.34	-0.59	1.0	-0.53	-0.23	0.24	0.24	-0.27
Other Current Assets	0.94	0.05	0.93	0.6	-0.7	0.5	0.78	-0.95	-0.53	0.98	0.92	0.77	0.91	0.63	0.92	-0.73	-0.67	0.34		0.39	0.41	0.6	0.67	0.94	0.94	0.48
Other Stockholder Equity	0.61	0.67	0.58	0.89	-0.65	0.97	0.83	-0.51	-0.92	0.21	0.65	0.87	0.33	0.43	0.65	-0.79	-0.2	-0.59	0.39		-0.53	0.89	0.89	0.55	0.55	0.92
Total Liab	0.26	-0.45	0.3	-0.47	-0.12	-0.48	-0.11	-0.27	0.2	0.5	0.17	-0.15	0.51	-0.15	0.17	-0.09	-0.63	1.0	0.41	-0.53		-0.47	-0.17	0.31	0.31	-0.22
Net Invested Capital	0.72	0.43	0.68	1.0	-0.62	0.95	0.83	-0.72	-0.75	0.49	0.78	0.88	0.5	0.76	0.78	-0.7	-0.16	-0.53	0.6	0.89	-0.47		0.82	0.67	0.67	0.72
Property Plant And Equipment Gross	0.78	0.7	0.75	0.82	-0.77	0.86	0.96	-0.68	-0.95	0.5	0.78	0.97	0.55	0.38	0.78	-0.9	-0.45	-0.23	0.67	0.89	-0.17	0.82		0.73	0.72	0.92
Total Current Assets	1.0	0.05	1.0	0.67	-0.8	0.66	0.79	-0.98	-0.69	0.88	0.99	0.8	0.96	0.67	0.99	-0.87	-0.73	0.24	0.94	0.55	0.31	0.67	0.73		1.0	0.65
Net Working Capital	1.0	0.05	1.0	0.67	-0.8	0.66	0.79	-0.98	-0.69	0.88	0.99	0.8	0.96	0.67	0.99	-0.87	-0.73	0.24	0.94	0.55	0.31	0.67	0.72	1.0		0.65
Property Plant Equipment	0.7	0.68	0.68	0.72	-0.78	0.86	0.84	-0.55	-1.0	0.28	0.69	0.87	0.47	0.24	0.69	-0.92	-0.45	-0.27	0.48	0.92	-0.22	0.72	0.92	0.65	0.65

Click cells to compare fundamentals

Talis Biomedical Account Relationship Matchups

Talis Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.7M	198.4M	265.8M	169.3M	98.3M	141.0M
Other Current Liab	2.5M	721K	1.1M	5.2M	4.6M	2.9M
Total Current Liabilities	4.0M	16.0M	19.1M	12.7M	8.8M	11.7M
Total Stockholder Equity	(21.1M)	(108.6M)	234.0M	126.7M	69.1M	45.5M
Net Tangible Assets	(21.1M)	(108.6M)	234.0M	126.7M	145.7M	153.0M
Property Plant And Equipment Net	1.5M	9.7M	23.4M	34.2M	15.4M	15.8M
Net Debt	(21.6M)	(137.8M)	(218.6M)	(96.6M)	(57.1M)	(59.9M)
Retained Earnings	(81.8M)	(172.9M)	(364.9M)	(478.0M)	(540.0M)	(513.0M)
Accounts Payable	1.6M	4.9M	5.1M	3.8M	1.3M	1.3M
Cash	21.6M	138.5M	232.5M	130.2M	76.7M	111.2M
Non Current Assets Total	1.6M	9.7M	29.7M	36.0M	20.7M	18.3M
Other Assets	91K	567K	29.7M	1.8M	1.0	0.95
Cash And Short Term Investments	21.6M	138.5M	232.5M	130.2M	76.7M	111.2M
Net Receivables	1.8M	471K	183K	308K	50K	47.5K
Common Stock Shares Outstanding	3.6M	290K	1.5M	1.8M	1.8M	1.5M
Liabilities And Stockholders Equity	25.7M	198.4M	265.8M	169.3M	98.3M	141.0M
Non Current Liabilities Total	42.8M	291.0M	12.7M	29.9M	20.5M	19.4M
Other Current Assets	697K	3.1M	3.4M	2.8M	901K	856.0K
Other Stockholder Equity	17.9M	(226.6M)	598.9M	604.7M	609.1M	639.5M
Total Liab	46.9M	307.0M	31.9M	42.6M	29.2M	27.8M
Net Invested Capital	(21.1M)	(108.6M)	234.0M	126.7M	69.1M	45.5M
Property Plant And Equipment Gross	1.5M	9.1M	23.4M	34.2M	28.4M	18.1M
Total Current Assets	24.1M	188.7M	236.1M	133.3M	77.7M	122.7M
Net Working Capital	20.1M	172.7M	217.0M	120.6M	68.9M	111.0M
Property Plant Equipment	1.5M	9.7M	23.4M	34.2M	39.4M	41.3M

Pair Trading with Talis Biomedical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Talis Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Talis Biomedical will appreciate offsetting losses from the drop in the long position's value.

Moving against Talis Stock

0.62	FNA	Paragon 28	Pair Corr
0.61	TFX	Teleflex Incorporated	Pair Corr
0.6	CAH	Cardinal Health Fiscal Year End 20th of August 2024	Pair Corr
0.58	SSY	SunLink Health Systems	Pair Corr
0.51	AHG	Akso Health Group	Pair Corr

The ability to find closely correlated positions to Talis Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Talis Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Talis Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Talis Biomedical Corp to buy it.

The correlation of Talis Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Talis Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Talis Biomedical Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Talis Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Talis Biomedical Corp is a strong investment it is important to analyze Talis Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Talis Biomedical's future performance. For an informed investment choice regarding Talis Stock, refer to the following important reports:

How To Invest In Talis

Details

Is Talis Stock a good investment?

Details

What is Talis Biomedical's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talis Biomedical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Talis Stock analysis

When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Talis Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Talis Biomedical. If investors know Talis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Talis Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(31.08)

Revenue Per Share

0.543

Quarterly Revenue Growth

(0.94)

Return On Assets

(0.34)

Return On Equity

(0.69)

The market value of Talis Biomedical Corp is measured differently than its book value, which is the value of Talis that is recorded on the company's balance sheet. Investors also form their own opinion of Talis Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Talis Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Talis Biomedical's market value can be influenced by many factors that don't directly affect Talis Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Talis Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Talis Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talis Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Talis Net Working Capital vs Total Liab Analysis

Net Working Capital vs Total Liab

Net Working Capital vs Total Liab Correlation Analysis

Correlation Coefficient

Net Working Capital

Total Liab

Talis Biomedical fundamental ratios Correlations

Talis Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Talis Biomedical fundamental ratios Accounts

Pair Trading with Talis Biomedical

Moving against Talis Stock

Complementary Tools for Talis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Current Liabilities
Net Working Capital	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity

Property Plant Equipment	- 1.0	Retained Earnings
Net Working Capital	- 0.98	Net Debt
Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Net Debt	- 0.97	Total Current Liabilities